Paramount’s action comedy Novocaine saw the brilliant Jack Quaid continue his strong 2025 run, following the late-January release of the widely acclaimed sci-fi thriller, Companion. Having just debuted in theaters across the most recent weekend,

March 2025 was never going to be huge at the domestic box office. While this time last year saw the movie release calendar populated with titles including Denis Villeneuve's Dune: Part Two, Mike Mitchell's Kung Fu Panda 4,

Novocaine could have been written by a 12-year-old, and I’m not sure I mean that pejoratively. It’s a riff on superhero stories, but it’s been thought up with a whiff of dopey plausibility: The film’s protagonist,

Quaid's leading role in Novocaine feels like a natural continuation of these genre-bent everymen. He plays Nathan Caine, a mild-mannered assistant bank manager who has congenital insensitivity to pain with anhidrosis (CIPA), a genetic disorder that impacts his nervous system to the point that he can't feel pain or temperature.

Jack Quaid’s action-comedy “Novocaine” topped a painfully slow weekend at the box office with $8.7 million. For theater owners, however, there’s not too much to celebrate: It’s one of the worst debuts to still capture the No.

Jack Quaid's new action film takes the top spot at the box office, knocking Bong Joon Ho's Mickey 17 into second place.